Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Sareum announces £700,000 fundraising to support drug development programmes

The company placed 100 mln new ordinary shares of 0.025p each at a price of 0.7p per share
drugs
Sareum is a specialist cancer drug discovery and development company

Sareum Holdings PLC (LON:SAR) has raised £700,000, before expenses, through a share placement to support drug development programmes and supply working capital.

The specialist cancer drug discovery and development company placed 100 million new ordinary shares of 0.025p each at a price of 0.7p per share.

READ: Latest preclinical data for Sareum’s cancer fighting Chk1 inhibitor impresses

Application has been made for the placing shares to be admitted to trading on the London Stock Exchange, which is expected to happen on 22 November.

The company will have a total of 2.7 billion shares in issue after the placing.

View full SAR profile View Profile

Sareum Holdings Plc Timeline

Related Articles

Pharmaceuticals
June 28 2018
The AIM-listed pharmaceuticals developer said the contract delays meant that its first-half revenue was expected to be “below management’s expectations”
researcher filling a vial
July 16 2018
The US Food & Drug Administration has given the company investigational new drug clearance for MCY-M11, a chimeric antigen receptor that targets solid tumours
Skin beauty
April 19 2018
In a note to clients initiating coverage on SkinBio, the joint ‘house’ broker noted that, as the skin microbiome group operates in a new therapeutic area, there is little market data in the sector

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use